difebarbamate, febarbamate, phenobarbital drug combination profile

difebarbamate, febarbamate, phenobarbital drug combination: combination of 15mg phenobarbital, 50mg febarbamate & 50mg difebarbamate; used to treat withdrawal in alcoholism; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	114965
SCHEMBL ID	1651427
MeSH ID	M0049287

Synonym
60763-47-5
difebarbamate, febarbamate, phenobarbital drug combination
atrium 300
2,4,6(1h,3h,5h)-pyrimidinetrione, 1,3-bis(2-((aminocarbonyl)oxy)-3-butoxypropyl)-5-ethyl-5-phenyl-, mixt. with 1-(2-((aminocarbonyl)oxy)-3-butoxypropyl)-5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrione and 5-ethyl-5-phenyl-2,4,6(1h,3h,5h)-pyrimidinetrion
difebarbamate - febarbamate - phenobarbital
atrium (drug)
SCHEMBL1651427
[1-butoxy-3-[3-(3-butoxy-2-carbamoyloxypropyl)-5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl]propan-2-yl] carbamate;[1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl] carbamate;5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

Excerpt	Relevance	Reference
" The two drugs were administered four times a day in double dummy conditions, according to a fixed-flexible decreasing dosage schedule (six days basic regimen)."	( Double blind study on the efficacy and safety of tetrabamate and chlordiazepoxide in the treatment of the acute alcohol withdrawal syndrome. Chabot, F; Chawla, S; Forest, JC; Garcin, F; Guay, D; Huot, J; Marquis, PA; Martin, S; Radouco-Thomas, S; Stewart, G, 1989)	0.28

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (23.81)	18.7374
1990's	10 (47.62)	18.2507
2000's	4 (19.05)	29.6817
2010's	2 (9.52)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (23.08%)	5.53%
Reviews	1 (3.85%)	6.00%
Case Studies	14 (53.85%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (19.23%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	3.36	1	1	benzodiazepine
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	1.98	1	0	imidazolidine-2,4-dione	anticonvulsant
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	7.78	21	3	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
chlormethiazole Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.	3.34	1	1	thiazoles
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	2	1	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
tiapamil hydrochloride Tiapamil Hydrochloride: A phenylethylamine derivative that acts as a calcium antagonist showing hemodynamic effects in patients with acute myocardial infarction.	3.35	1	1

Condition	Relationship Strength	Studies	Trials
Diathesis [description not available]	2.05	1	0
Auricular Fibrillation [description not available]	2.46	2	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.05	1	0
Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.	2.46	2	0
Esophageal Reflux [description not available]	2.05	1	0
Cardiac Diseases [description not available]	2.05	1	0
Esophageal Fistula Abnormal passage communicating with the ESOPHAGUS. The most common type is TRACHEOESOPHAGEAL FISTULA between the esophagus and the TRACHEA.	2.05	1	0
Gastroesophageal Reflux Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.	2.05	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	2.05	1	0
Atrial Septal Defect [description not available]	2.06	1	0
Intraventricular Septal Defects [description not available]	2.06	1	0
Heart Septal Defects, Ventricular Developmental abnormalities in any portion of the VENTRICULAR SEPTUM resulting in abnormal communications between the two lower chambers of the heart. Classification of ventricular septal defects is based on location of the communication, such as perimembranous, inlet, outlet (infundibular), central muscular, marginal muscular, or apical muscular defect.	2.06	1	0
Acute Liver Injury, Drug-Induced [description not available]	4.51	9	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	4.51	9	0
Alcohol Abuse [description not available]	4.27	4	1
Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)	4.27	4	1
Drug Withdrawal Symptoms [description not available]	4.84	4	2
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	1.98	1	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	4.84	4	2
Acute Hepatic Failure [description not available]	1.98	1	0
Liver Failure, Acute A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.	1.98	1	0
Psychoses [description not available]	1.98	1	0
Acute Disease Disease having a short and relatively severe course.	2.39	2	0
Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)	1.98	1	0
Depression, Endogenous [description not available]	1.98	1	0
Liver Steatosis [description not available]	1.98	1	0
Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.	1.98	1	0
Fatty Liver Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.	1.98	1	0
Hepatic Failure [description not available]	2	1	0
Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)	2	1	0
AIDS Seroconversion [description not available]	1.98	1	0
Drug-Induced Stevens Johnson Syndrome [description not available]	1.98	1	0
Stevens-Johnson Syndrome Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.	1.98	1	0
Action Tremor [description not available]	1.98	1	0
Tremor Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.	1.98	1	0
Alcohol Withdrawal Associated Autonomic Hyperactivity [description not available]	1.97	1	0
Claustrophobia [description not available]	1.97	1	0
Agoraphobia Obsessive, persistent, intense fear of open places.	1.97	1	0
Phobic Disorders Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.	1.97	1	0

difebarbamate, febarbamate, phenobarbital drug combination

Description

Cross-References

Synonyms (8)

Research Excerpts

Dosage Studied

Research

Studies (21)

Market Indicators

Research Demand Index: 10.91

Study Types